News | September 18, 2025
Novo Nordisk’s Wegovy delivered 16.6% weight loss
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Subscribe To Our Newsletter & Stay Updated
